Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gonyautoxin is a marine toxin that belongs to the saxitoxin family. It exists in several forms (numbered as GTX1, GTX2, GTX3, GTX5, etc.) and has been investigated for medical applications, particularly for pain management. Gonyautoxin is a phycotoxin that works by reversibly blocking voltage-gated sodium channels at the axonal level, which impedes nerve impulse propagation[5]. This mechanism makes it potentially useful for pain management applications. The molecular structure is based on a 2,6-diamino-4-methyl-pyrollo[1,2-c]-purin-10-ol skeleton, with different gonyautoxin variants (GTX1, GTX2, GTX3, etc.) differing only by their substituents or stereoisomerism[3]. Gonyautoxin has been investigated in clinical trials for treating acute back pain and has shown promise in treating chronic tension-type headache[5]. In one study, patients reported significant pain relief within minutes after local infiltration of gonyautoxin, with no side effects detected during the follow-up period[5]. The compound is naturally produced by marine dinoflagellates like Gonyaulax and Protogonyaulax species and can be isolated from shellfish[9]. While it's naturally available, synthesis procedures for some gonyautoxin variants have been developed[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gonyautoxin.